Cargando…

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

BACKGROUND: This study was designed to investigate the clinical application, efficacy, and safety of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer in the real world. METHODS: A retrospective, observational analysis was conducted on patients treated with ICIs in four tertiary ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Meiling, Ji, Huaijun, Xu, Ning, Jiang, Peng, Qu, Tao, Li, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277844/ https://www.ncbi.nlm.nih.gov/pubmed/35831785 http://dx.doi.org/10.1186/s12885-022-09843-3

Ejemplares similares

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis
por: Meng, Lingbin, et al.
Publicado: (2023)

Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
por: Hanna, Glenn J., et al.
Publicado: (2020)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
por: Ferraresi, Virginia, et al.
Publicado: (2021)

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
por: Hsu, Jason C., et al.
Publicado: (2021)

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
por: Horibe, Ryota, et al.
Publicado: (2021)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
por: Al Nuhait, Mohammed, et al.
Publicado: (2021)

COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Guo, Mengni, et al.
Publicado: (2022)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
por: Wang, Hui-Ching, et al.
Publicado: (2020)

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
por: Puppa, G, et al.
Publicado: (2007)

Radiochemotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer
por: Schäfer, C, et al.
Publicado: (2006)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre
por: Koch Hein, Erica C., et al.
Publicado: (2023)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma
por: Davies, Rhian Siân, et al.
Publicado: (2017)

CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors
por: Li, Jiazheng, et al.
Publicado: (2023)

Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System
por: La, Jennifer, et al.
Publicado: (2020)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
por: Gao, Yinjie, et al.
Publicado: (2022)

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis
por: Hoffmann, Michèle, et al.
Publicado: (2022)

c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients
por: Lin, Shu-Hui, et al.
Publicado: (2019)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
por: Zhang, Shijia, et al.
Publicado: (2021)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
por: Kao, Ming-Wei, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6tt1lva4piou6lcrg1u250van8